Quantcast

Pfizer recalls 1 million ineffective birth control pill packs

By Megan Carpentier
Wednesday, February 1, 2012 10:02 EDT
google plus icon
A positive pregnancy test, via William J. Serson on Flickr, Creative Commones licensed.
 
  • Print Friendly and PDF
  • Email this page

Pfizer announced a recall of approximately 1 million birth control pill packs in the United States and warned users of the recalled pills to start using back-up methods immediately to prevent pregnancy.

The pills recalled are marketed under the name Lo/Ovral-28 and as generic Norgestrel/Ethinyl Estradiol as sold by Akrimax Pharmaceuticals. (A full list of lot numbers subject to recall is available here.) Pfizer told the Associated Press that tests revealed that quality control was at issue with the affected lots: “some packets of the drugs had too many active tablets, while others had too few.”

While there is no safety risk to the pills, users with packets that contain placebos instead of active pills are effectively — and unknowingly — not protected against pregnancy while taking those pills, and potentially for the month after as their bodies readjust. Users are encouraged to tell their doctors and return the affected pills to their pharmacies.

More than 10 million American women use hormonal birth control pills for contraception, and it’s the most common method of contraception among women under 30. More than half of women who have abortions report that they got pregnant due to contraception failure.

Megan Carpentier
Megan Carpentier is the executive editor of Raw Story. She previously served as an associate editor at Talking Points Memo; the editor of news and politics at Air America; an editor at Jezebel.com; and an associate editor at Wonkette. Her published works include pieces for the Washington Post, the Washington Independent, Ms Magazine, RH Reality Check, the Women's Media Center, On the Issues, the New York Press, Bitch and Women's eNews.
 
 
 
 
By commenting, you agree to our terms of service
and to abide by our commenting policy.
 
Google+